araag2/HINT huggingface dataset:
Clinical trial NCT02985983 (phase 3, status: completed)
Conditions: axial spondyloarthritis
ICD codes: M45.A1, M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7
Drugs: khk4827, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with age at onset <45 years and continuous chronic back pain for ≥ 3 months
             fulfills the ASAS classification criteria of axial spondyloarthritis (with the
             exception of the Crohn's disease)

          -  Subject has Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at
             screening and enrollment

          -  Subject has spinal pain score (BASDAI question #2) ≥ 4 at screening and enrollment

          -  Subject has had adequate therapy with non-steroidal anti-inflammatory drugs (oral
             NSAIDs) for back pain for at least 3 months with inadequate treatment response before
             enrollment

        Exclusion Criteria:

          -  Complete ankylosis (fusion) of the spine

          -  Subject with active ongoing inflammatory diseases other than axSpA that might confound
             the evaluation of KHK4827 therapy, including reactive arthritis, spondyloarthritis
             associated with inflammatory bowel disease, SAPHO syndrome (pustulotic
             arthro-osteitis), fibromyalgia, ankylosing spinal hyperostosis, osteitis condensans
             ilii, spondylosis deformans, or osteoarthritis sacroiliac joint disease

          -  Subject has a prior history of >1 anti-TNF therapy

          -  Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any
             suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating
             Scale (C-SSRS) at enrollment

          -  Subject has a history or evidence of a psychiatric disorder, alcohol and/or substance
             abuse

          -  Subject has severe depression based on a total score of ≥ 15 on the Patient Health
             Questionnaire-8 (PHQ-8) at enrollment (note: subjects with a total score of 10 to 14
             on the PHQ-8 should be referred to a mental health care professional)
Clinical trial NCT02987543 (phase 3, status: active, not recruiting)
Conditions: metastatic castration-resistant prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: olaparib, enzalutamide, abiraterone acetate, abiraterone acetate, enzalutamide
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion criteria

          1. Histologically confirmed diagnosis of prostate cancer.

          2. Documented evidence of metastatic castration resistant prostate cancer (mCRPC).

          3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate
             and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .

          4. Ongoing therapy with LHRH analog or bilateral orchiectomy.

          5. Radiographic progression at study entry while on androgen deprivation therapy (or
             after bilateral orchiectomy).

          6. Qualifying HRR mutation in tumor tissue.

        Exclusion criteria

          1. Any previous treatment with PARP inhibitor, including olaparib.

          2. Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy,
             except if for non-prostate cancer indication and last dose > 5 years prior to
             randomization.

          3. Other malignancy (including MDS and MGUS) within the last 5 years except: adequately
             treated non-melanoma skin cancer or other solid tumors curatively treated with no
             evidence of disease for ≥5 years.

          4. Subjects with known brain metastases.
Clinical trial NCT02988115 (phase 3, status: completed)
Conditions: hypercholesterolemia, atherosclerotic cardiovascular disease, statin adverse reaction
ICD codes: E78.01, E78.00, Z83.42, Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24, D72.823, F43.0, L43.2, R50.84, T80.92XS, F43.9, T80.92XA
Drugs: bempedoic acid
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Require lipid-modifying therapy for primary or secondary prevention of cardiovascular
             disease

          -  Fasting LDL-C ≥130 mg/dL for primary prevention or LDL-C ≥100 mg/dL for secondary
             prevention (history of HeFH and/or ASCVD)

          -  Be statin-intolerant (unable to tolerate 2 or more statins)

        Exclusion Criteria:

          -  Total fasting triglyceride ≥500 mg/dL

          -  Renal dysfunction or nephrotic syndrome or history of nephritis

          -  Body Mass Index (BMI) ≥50 kg/m2

          -  Significant cardiovascular disease or cardiovascular event in the past 3 months
Clinical trial NCT02990546 (phase 3, status: terminated)
Conditions: septic shock
ICD codes: T81.12XS, R65.20, R65.21, T81.12XA, T81.12XD
Drugs: midodrine
SMILES: COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1
Reason stopped: 
    unable to meet enrollment goals
  
Eligibility criteria:

        Inclusion Criteria:

          -  • Patients aged 18-99 years old

               -  Admitted to UVA medical ICU with diagnosis of septic shock.

        Exclusion Criteria:

          -  Pregnant females, patients with childbearing potential will have urine pregnancy
             testing after consent

          -  Patients < 18 years

          -  Prisoners

          -  Patients already taking midodrine

          -  Patients with cirrhosis and Child-Pugh Class C (Child-Pugh score > 9)_

          -  Patients with Increased intraocular pressure and glaucoma

          -  Patients with allergy to midodrine

          -  Non-English speaking patients

          -  Patients without enteral access

          -  Patients where the attending physician does not feel MAP goal of > 65 mmHg is
             physiologically acceptable.
Clinical trial NCT02991118 (phase 3, status: completed)
Conditions: hypercholesterolemia, atherosclerotic cardiovascular disease
ICD codes: E78.01, E78.00, Z83.42, Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: bempedoic acid, placebo
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting LDL-C ≥100 mg/dL

          -  High cardiovascular risk (diagnosis of HeFH and/or ASCVD)

          -  Be on maximally tolerated lipid-modifying therapy (LMT), including maximally tolerated
             statin either alone or in combination with other LMTs

        Exclusion Criteria:

          -  Total fasting triglyceride ≥500 mg/dL

          -  Renal dysfunction or nephrotic syndrome or history of nephritis

          -  Body Mass Index (BMI) ≥50kg/m2

          -  Significant cardiovascular disease or cardiovascular event in the past 3 months
Clinical trial NCT02996682 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel, rbv
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Chronic HCV-infected males and non-pregnant/non-lactating females

          -  Treatment naive or treatment experienced individuals

          -  Child-Pugh-Turcotte Score 7-12 at screening

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02997501 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: azd9291 dosing
SMILES: COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures.

          2. Adults (according to China regulations for age of majority)

          3. Histological or cytological confirmed locally advanced NSCLC (stage IIIB) or
             metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy.

          4. Patients who have progressed following prior therapy with an EGFR-TKI agent.

        Exclusion Criteria:

          1. Patients who disagree to participate this study.

          2. Patients whose medical objection was recorded to use the existing data from medical
             practice for scientific research.
Clinical trial NCT03001076 (phase 3, status: completed)
Conditions: hypercholesterolemia, atherosclerosis, statin adverse reaction
ICD codes: E78.01, E78.00, Z83.42, I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83, D72.823, F43.0, L43.2, R50.84, T80.92XS, F43.9, T80.92XA
Drugs: bempedoic acid, ezetimibe
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting LDL-cholesterol greater than or equal to 100 mg/dL at screening

          -  Men and nonpregnant, nonlactating women

          -  Use of stable lipid-modifying therapy for at least 4 weeks prior to screening that
             includes ezetimibe 10mg daily

        Exclusion Criteria:

          -  Fasting blood triglycerides greater than or equal to 500 mg/dL

          -  Body Mass Index (BMI) greater than or equal to 50 kg/m2

          -  Recent history of clinically significant cardiovascular disease

          -  Use of statin therapy where doses are greater than those defined as "low-dose" within
             4 weeks prior to screening; where "low-dose" is defined as an average daily dose of
             rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg,
             pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.
Clinical trial NCT03006276 (phase 3, status: completed)
Conditions: migraine headache
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: dfn-15 active
SMILES: CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for
             at least the past 12 months, with no more than 14 headache days per month, and with 48
             hours of headache-free time between migraine attacks.

          2. Patients who have migraine with or without aura with onset before age 50 years

          3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity
             scale without treatment.

          4. Subjects who are willing and able to:

               1. Evaluate and record pain, migraine symptoms, and study drug effectiveness
                  information in real-time using a subject eDiary for the duration of the study;

               2. Record each instance of the use of study drug and rescue medication in real-time
                  using a subject eDiary for the duration of the study;

               3. Comply with all other study procedures and scheduling requirements.

        Exclusion Criteria:

          1. Minors, even if they are in the specified study age range

          2. Medication overuse:

               1. Opioids greater than or equal to 10 days during the 90 days prior to screening

               2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during
                  the 90 days prior to screening (applies only if includes opioid and/or
                  barbiturate)

               3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14
                  days a month during the 90 days prior to screening

               4. Triptans or ergots greater than or equal to 10 days a month during the 90 days
                  prior to screening

          3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to
             screening. (If treated for cosmetic reasons, subjects may be included).

          4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to
             randomization.

          5. Patients who have received treatment with an investigational drug or device within 30
             days of randomization, or participated in a central nervous system clinical trial
             within 2 months prior to randomization

          6. Patients with positive screening test for human immunodeficiency virus [HIV], positive
             hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody

          7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any
             of its affiliates or partners, or of the clinical research study site.
Clinical trial NCT03009019 (phase 3, status: completed)
Conditions: migraine headache
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: dfn-15 active
SMILES: CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for
             at least the past 12 months, with no more than 14 headache days per month, and with 48
             hours of headache-free time between migraine attacks.

          2. Patients who have migraine with or without aura with onset before age 50 years

          3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity
             scale without treatment.

          4. Subjects who are willing and able to:

               1. Evaluate and record pain, migraine symptoms, and study drug effectiveness
                  information in real-time using a subject eDiary for the duration of the study;

               2. Record each instance of the use of study drug and rescue medication in real-time
                  using a subject eDiary for the duration of the study;

               3. Comply with all other study procedures and scheduling requirements.

        Exclusion Criteria:

          1. Minors, even if they are in the specified study age range

          2. Medication overuse:

               1. Opioids greater than or equal to 10 days during the 90 days prior to screening

               2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during
                  the 90 days prior to screening (applies only if includes opioid and/or
                  barbiturate)

               3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14
                  days a month during the 90 days prior to screening

               4. Triptans or ergots greater than or equal to 10 days a month during the 90 days
                  prior to screening

          3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to
             screening. (If treated for cosmetic reasons, subjects may be included).

          4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to
             randomization.

          5. Patients who have received treatment with an investigational drug or device within 30
             days of randomization, or participated in a central nervous system clinical trial
             within 2 months prior to randomization

          6. Patients with positive screening test for human immunodeficiency virus [HIV], positive
             hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody

          7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any
             of its affiliates or partners, or of the clinical research study site.
Clinical trial NCT03009136 (phase 3, status: unknown status)
Conditions: perennial allergic rhinitis
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: scrt, placebos
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. age 18-60 years

          2. presence of two or more nasal symptoms (rhinorrhea, nasal congestion, nasal itching
             and sneezing) with severity score ≥ 2 (0 = no symptom, 1 = mild symptom, 2 = moderate
             symptom, and 3=severe symptom)

          3. presence of nasal symptoms more than 2 consecutive years; and

          4. positive reaction to the one or more perennial allergen in skin prick test.

        Exclusion Criteria:

          1. treatment with nasal/oral corticosteroids within the past month; nasal cromolyn or
             tricyclic antidepressants within the past two weeks; or nasal/oral decongestants,
             nasal/oral antihistamines, or antileukotrienes within the past week

          2. presence of rhinosinusitis (paranasal sinus X-ray demonstrating mucosal thickening, or
             partial or complete opacification of the paranasal sinuses)

          3. presence of hypertension (systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg)

          4. presence of abnormal liver function (aspartate transaminase (AST) or alanine
             transaminase (ALT) ≥ 100 IU/L) or abnormal renal function (blood urea nitrogen (BUN) ≥
             30 mg/dL or creatinine ≥ 1.8 mg/dL (male), 1.5 mg/dL (female))

          5. presence of neoplasm, severe systemic inflammation, other systemic disease that
             affects rhinitis

          6. history of drug allergy

          7. history of anaphylaxis for allergic tests

          8. pregnancy or lactation

          9. participation of other clinical study within the past 3 months.
Clinical trial NCT03020082 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: danoprevir, ritonavir, peginterferon alfa-2a, rbv
SMILES: CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months)

          -  Serum HCV RNA of ≥ 1 × 104 IU/mL are documented

          -  Hepatitis C virus GT1

          -  Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or
             host-targeting antivirals for HCV

          -  Non-cirrhosis patients: Non-cirrhosis is defined (1)Fibroscan defined as: ˂ 14.6 kPa
             during screening period, or liver biopsy determined 1 year before recruiting (Metavir
             score ˂ 3);(2) during screening period 9.6<Fibroscan indicator ≤12.9, liver biopsy
             need to confirm non-cirrhosis.

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Patients with Fibroscan detection value > 12.9 kPa, or histologic examination for
             liver cirrhosis patients

          -  Presence or history of non-hepatitis C chronic liver disease (e.g. HH, AIH, Wilson's
             disease, α1 antitrypsin deficiency, drug- or toxin-induced liver disease)

          -  History of liver cell cancer, or suspected hepatocellular carcinoma (HCC) patients
             before or during screening , or imaging studies found suspicious nodules, or AFP > 50
             ng/mL

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody

          -  Presence or history of nervous system diseases and/or mental illness, inability to
             control oneself or express oneself.

          -  Patients with obvious cardiovascular dysfunction

          -  Pregnant or nursing female, nor unwilling to take reliable contraception

          -  Others as specified in the detailed protocol
Clinical trial NCT03033511 (phase 3, status: terminated)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: placebo for dexamethasone, placebo for rovalpituzumab tesirine, rovalpituzumab tesirine, dexamethasone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    independent data monitoring committee recommendation
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed extensive-stage disease small cell lung
             cancer (ED SCLC) at initial diagnosis with ongoing clinical benefit (stable disease
             [SD], partial response [PR], or complete response [CR]) following completion of 4
             cycles of first-line platinum-based therapy

          -  Participant is eligible to be randomized at least 3 but no more than 9 weeks from Day
             1 of the fourth cycle of first-line platinum-based chemotherapy.

          -  Participants with a history of central nervous system (CNS) metastases prior to the
             initiation of first-line platinum-based chemotherapy must have received definitive
             local treatment and have documentation of stable or improved CNS disease status

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

          -  Participants must have adequate bone marrow, renal and hepatic function

          -  Availability of archived or representative tumor material for assessment of DLL3
             expression

        Exclusion Criteria:

          -  Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint
             inhibitors, other monoclonal antibodies, antibody-drug conjugates,
             radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any other
             anti-cancer therapy than that described in inclusion criteria for SCLC.

          -  Any disease-directed radiotherapy (except prophylactic cranial irradiation, palliative
             radiotherapy to a radiographically documented non-progressing lesion for symptom
             control, or pre-planned radiotherapy for CNS metastases present prior to start of
             first-line therapy and non-progressing) after last dose of first-line chemotherapy.

          -  Prior exposure to a pyrrolobenzodiazepine (PBD-based) or indolinobenzodiazepine-based
             drug, prior participation in a rovalpituzumab tesirine clinical trial, or known
             hypersensitivity or other contraindications to rovalpituzumab tesirine or excipient
             contained in the drug formulation.